Envoy Medical Updates Third Quarter 2026 Earnings Call Time to 8:00 A.M. ET on Thursday, November 5th

Financial Results to Be Released Before Market Open

White Bear Lake, Minnesota--(Newsfile Corp. - October 28, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it has updated the time of its conference call to discuss financial results for the third quarter ended September 30, 2026. The conference call will now be held at 8:00 A.M. ET on Thursday, November 5, 2026. The Company will report its third quarter financial results before the market opens on the same day.

Third Quarter 2026 Financial Results Conference Call:
Date: Thursday, November 5, 2026
Time: 8:00 A.M. ET
Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1778210&tp_key=20071611a1

For interested individuals unable to join the conference call, a replay will be available through November 19, 2026, by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11162715.

To be added to the Envoy Medical email distribution list, please email [email protected] with COCH in the subject line.

About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health and neuroprosthetics company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.

Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/321373